Page last updated: 2024-08-26

4-hydroxycyclophosphamide and carboplatin

4-hydroxycyclophosphamide has been researched along with carboplatin in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beijnen, JH; Dalesio, O; de Jonge, ME; Huitema, AD; Mathôt, RA; Rodenhuis, S	1
Finkler, NJ; Fruehauf, JP; Holloway, RW; Li, KT; McLaren, CE; Mehta, RS; Parker, RJ	1
Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ	1
Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; van Dam, SM	1

Trials

2 trial(s) available for 4-hydroxycyclophosphamide and carboplatin

Article	Year
Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecologic oncology, 2002, Volume: 87, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Cyclophosphamide; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate; Treatment Outcome	2002
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. Therapeutic drug monitoring, 2005, Volume: 27, Issue:6 Topics: Adolescent; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Phosphoramide Mustards; Prodrugs; Thiotepa; Time Factors; Triethylenephosphoramide	2005

Article

Year

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Gynecologic oncology, 2002, Volume: 87, Issue:1

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Cyclophosphamide; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate; Treatment Outcome

2002

Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.

Therapeutic drug monitoring, 2005, Volume: 27, Issue:6

Topics: Adolescent; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Phosphoramide Mustards; Prodrugs; Thiotepa; Time Factors; Triethylenephosphoramide

2005

Other Studies

2 other study(ies) available for 4-hydroxycyclophosphamide and carboplatin

Article	Year
Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. Bone marrow transplantation, 2002, Volume: 30, Issue:9 Topics: Adolescent; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cyclophosphamide; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Thiotepa; Triethylenephosphoramide	2002
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. Journal of the National Cancer Institute, 2004, May-19, Volume: 96, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine	2004

Article

Year

Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.

Bone marrow transplantation, 2002, Volume: 30, Issue:9

Topics: Adolescent; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cyclophosphamide; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Thiotepa; Triethylenephosphoramide

2002

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Journal of the National Cancer Institute, 2004, May-19, Volume: 96, Issue:10

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine

2004